Bronchiectasis and Bronchitis Diagnosis and Management

Definition and Pathophysiology

• Bronchiectasis is a chronic respiratory disease characterized by permanent dilation of the bronchi, visible on CT scan, with clinical symptoms of cough, sputum production, and recurrent respiratory infections, as defined by the European Respiratory Society 1, 2
• The American Thoracic Society recommends that bronchiectasis diagnosis requires both clinical symptoms and radiological confirmation (permanent bronchial dilation on CT scan) 1, 3

Structural Changes and Diagnostic Criteria

• Bronchiectasis involves destruction of elastic and muscular components of bronchial walls, leading to permanent and abnormal dilation of the airways, according to the European Respiratory Journal 2, 4
• The European Respiratory Society states that high-resolution CT (HRCT) is essential for bronchiectasis diagnosis, showing abnormal dilation of bronchi 2

Etiology and Clinical Presentation

• Bronchiectasis often results from focal causes, such as bronchial obstruction, and diffuse causes, including immunodeficiencies and primary ciliary dyskinesia, as reported in the Chest journal 2, 4
• The European Respiratory Journal notes that bronchiectasis is characterized by chronic productive cough, recurrent respiratory infections, hemoptysis, and sometimes clubbing 2, 4

Management and Clinical Implications

• The European Respiratory Society recommends that bronchiectasis management may require long-term antibiotic therapy (oral or inhaled) for pathogen eradication and exacerbation prevention 5, 6
• Regular airway clearance techniques are essential components of bronchiectasis management, according to the European Respiratory Journal 5, 7
• The American Thoracic Society states that bronchiectasis is a progressive condition that can lead to respiratory failure if untreated, with significant impairment in quality of life, equivalent to severe COPD 1, 5
• Exacerbations in bronchiectasis are associated with increased inflammation, accelerated lung function decline, and higher mortality, as reported in the European Respiratory Journal 5, 7

Bronchiectasis Development and Management

Pathophysiology and Inflammatory Mechanisms

• The European Respiratory Society notes that bronchiectasis involves a vicious cycle of chronic bronchial infection, inflammation, impaired mucociliary clearance, and structural lung damage 8, 9
• Chronic inflammation from emphysema leads to destruction of bronchial wall components, predisposing to bronchiectasis, as reported by the American College of Chest Physicians 10
• Impaired mucociliary clearance in COPD leads to mucus stasis, bacterial colonization, and subsequent bronchial damage, according to the European Respiratory Journal 9
• Neutrophilic inflammation is the hallmark of bronchiectasis, with neutrophil elastase and collagenase contributing to destruction of bronchial walls, as stated by the American College of Chest Physicians 10
• Excessive neutrophilic inflammation is linked to increased frequency of exacerbations and rapid lung function decline through degradation of airway elastin, as noted by the European Respiratory Journal 9

Clinical Significance and Management

• Breathlessness in patients with both bronchiectasis and COPD is due to airflow obstruction, impaired gas transfer, exercise deconditioning, and comorbidities, as reported by the European Respiratory Journal 11
• Mortality risk increases significantly, with up to 30% mortality at 1-year follow-up after an exacerbation, particularly in the presence of COPD, according to the European Respiratory Journal 11
• Treatment aims to prevent exacerbations, reduce symptoms, improve quality of life, and stop disease progression, as stated by the European Respiratory Journal 9
• Bronchodilators are used to address airflow obstruction, as recommended by the American College of Chest Physicians 10
• Pulmonary rehabilitation is used to improve exercise capacity, as reported by the European Respiratory Journal 11

Diagnostic Approach and Management of Bronchiectasis

Diagnostic Criteria and Preventive Measures

• The European Respiratory Society recommends a minimum panel of tests for children/adolescents with suspected or confirmed bronchiectasis, including lower airway bacteriology 12
• Strategies to prevent bronchiectasis include addressing household crowding, prematurity, and preventing frequent, early-onset and severe acute lower respiratory tract infections 12
• Early diagnosis and intervention are important to potentially reverse bronchial wall dilatation in early disease 13

Implementation and Management

• Access and strategies to improve early diagnosis and interventions to prevent and/or reverse bronchiectasis are required 12

Diagnosis and Management of Bronchiectasis

Clinical Presentation and Diagnosis

• The presence of diffuse wheezes and bibasilar crackles in a patient is consistent with bronchiectasis, as noted by the American Thoracic Society 14, 15
• High-resolution CT (HRCT) with IV contrast is the diagnostic procedure of choice to confirm bronchiectasis, with sensitivity and specificity exceeding 90%, according to the American College of Radiology 14, 15
• Sputum cultures for routine bacteria, acid-fast bacilli, and fungi are essential in the diagnosis of bronchiectasis, as recommended by the Infectious Diseases Society of America 14, 15
• Blood cultures should be obtained to rule out endocarditis, especially in patients with a history of IV drug use, as suggested by the American Heart Association 15

Systematic Evaluation for Underlying Causes

• A diagnostic evaluation for an underlying disorder causing bronchiectasis should be performed, because the results may lead to treatment that may slow or halt disease progression, as recommended by the European Respiratory Society 14, 15
• Infectious causes, such as tuberculosis and atypical mycobacteria (MAC), should be investigated, especially in patients with a history of IV drug use, as noted by the Centers for Disease Control and Prevention 14
• Post-infectious bronchiectasis should be considered, as many cases result from permanent bronchial wall damage after respiratory infections, according to the American Thoracic Society 14, 15

Management Principles

• Do not assume that the patient has simple bronchiectasis, as the IV drug use history mandates investigation for endocarditis, tuberculosis, and HIV-related disease before attributing symptoms to bronchiectasis alone, as recommended by the American College of Physicians 15
• Do not rely on chest radiography alone, as up to 34% of chest radiographs are unremarkable in patients with CT-proven bronchiectasis, according to the Journal of the American College of Radiology 16
• HRCT is essential for the diagnosis of bronchiectasis, as noted by the American College of Radiology 14, 15, 16

Pneumonia Risk and Prevention in Bronchiectasis

Prevention Strategies

• The British Thoracic Society recommends annual influenza immunization for all bronchiectasis patients to reduce the risk of pneumonic exacerbations 17
• The British Thoracic Society recommends polysaccharide pneumococcal vaccination for all bronchiectasis patients to reduce the risk of pneumonic exacerbations 17
• The British Thoracic Society suggests considering 13-valent protein conjugate pneumococcal vaccine in patients without appropriate serological response to standard 23-valent vaccine 17
• The British Thoracic Society recommends considering influenza vaccination in household contacts of immunodeficient patients to reduce secondary transmission 17

Management Implications

• The British Thoracic Society recommends eradication therapy for new growth of P. aeruginosa or MRSA, particularly with clinical deterioration 17

Diagnostic Criteria for Bronchiectasis

Imaging Modalities

• The British Thoracic Society recommends thin-section CT (either conventional HRCT or volumetric thin-slice CT) as the preferred examination for diagnosing bronchiectasis 18, 19
• Thin-section CT without contrast is the examination of choice for confirming the diagnosis of bronchiectasis, according to the American College of Radiology 18, 19
• A protocol CT for interstitial lung disease with a slice thickness of 1.5 mm can be used to identify and characterize various chronic diffuse lung diseases associated with bronchiectasis 18, 19

Diagnostic Criteria on CT

• Bronchiectasis is defined by bronchial dilatation, as indicated by one or more of the following: a bronchoarterial ratio >1, lack of tapering, or visibility of airways within 1 cm of the costal pleura or abutting the mediastinal pleura 20, 21, 22, 19
• The bronchoarterial ratio >1 is a key diagnostic criterion, where the internal diameter of the bronchus is greater than that of the adjacent pulmonary artery 20, 21, 22, 19
• Lack of tapering of the bronchi is another diagnostic criterion, where the bronchi do not progressively decrease in size from central to peripheral 20, 21, 22, 19

Prognostic Value of CT

• CT can quantify the extent and severity of bronchiectasis using various techniques and software, which has prognostic value for outcomes such as exacerbations, hospitalizations, and mortality 18, 19
• The presence of bronchiectasis in at least 3 lobes on CT is associated with a worse outcome and is included in the bronchiectasis severity score with a relatively high predictive value for exacerbations, hospitalizations, and mortality 18, 19
• The severity of bronchiectasis on CT correlates with the degree of airflow obstruction 18, 19